

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION
APPROVAL FROM CHINA SECURITIES REGULATORY COMMISSION ON
ISSUANCE OF H SHARE CONVERTIBLE BONDS

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company received the approval (the “**Approval**”) on the Company’s proposal in respect of the issue of corporate bonds (the “**Convertible Bonds**”) convertible into H shares of the Company (the “**H Shares**”) from the China Securities Regulatory Commission, under which the Company is approved to issue the Convertible Bonds of no more than HK\$6 billion (or the equivalent in other foreign currencies), and the additional H Shares to be issued by exercise of conversion rights by holders of the Convertible Bonds are permitted to be listed on the Main Board of the Stock Exchange, subject to the approval of the Stock Exchange. The Approval will be valid within 12 months since the date of the Approval.

The Company will, subject to the market condition, select an appropriate time to proceed with all matters in connection with the issue of the Convertible Bonds in accordance with the requirements under the Listing Rules and relevant laws and regulations, and will fulfill its information disclosure obligations under the Listing Rules on a timely basis. **Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, April 19, 2022

As of the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.